Allergan rebuffed in seeking offers to combat Valeant bid-report
(Refiled to remove extraneous text characters in headline)
May 11 (Reuters) - U.S. medical firm Allergan Inc declined to comment on Sunday on a report that it has been seeking offers from rival companies to combat Valeant Pharmaceuticals International's $47 billion cash and share offer.
A spokeswoman for Allergan told Reuters on Sunday the company had no comment to make on whether it was seeking offers from other companies, following a report by Bloomberg that Allergan has so far been rebuffed by rival companies it has tried to interest in making an offer.
Allergan contacted both Sanofi SA and Johnson & Johnson after Valeant made its offer on April 22, Bloomberg said, as well as GlaxoSmithKline Plc and Novartis AG. (Reporting by Scott DiSavino; Editing by Greg Mahlich)
© Thomson Reuters 2016 All rights reserved.